BTC Capital Management Inc. Sells 300 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

BTC Capital Management Inc. decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.6% during the first quarter, HoldingsChannel reports. The fund owned 49,353 shares of the specialty pharmaceutical company’s stock after selling 300 shares during the quarter. BTC Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $6,128,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of JAZZ. Versant Capital Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 9.4% in the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 91 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 0.3% in the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock worth $3,317,000 after purchasing an additional 92 shares during the last quarter. CIBC Asset Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after purchasing an additional 97 shares during the last quarter. Synovus Financial Corp lifted its stake in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock worth $2,365,000 after acquiring an additional 100 shares during the period. Finally, Quarry LP lifted its stake in Jazz Pharmaceuticals by 6.3% in the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $209,000 after acquiring an additional 100 shares during the period. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Barclays reissued an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.79.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Seamus Mulligan purchased 1,621 shares of Jazz Pharmaceuticals stock in a transaction on Monday, May 12th. The stock was bought at an average cost of $103.00 per share, with a total value of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company’s stock, valued at $10,466,963. This represents a 1.62% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the sale, the chief executive officer now directly owns 439,307 shares in the company, valued at $51,113,369.45. The trade was a 0.23% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,623 shares of company stock valued at $2,710,591. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $108.28 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $6.67 billion, a PE ratio of 15.25, a P/E/G ratio of 1.04 and a beta of 0.38. The firm has a 50 day moving average of $109.72 and a two-hundred day moving average of $121.41.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million for the quarter, compared to analysts’ expectations of $984.16 million. During the same period in the prior year, the business posted $2.68 earnings per share. The business’s quarterly revenue was down .5% compared to the same quarter last year. On average, analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.